Table 1.
Patient demographic and baseline characteristics.
| Glargine (n = 678) | BIL (n = 691) | |
|---|---|---|
| Age, years | 57.8 ± 9.2 | 57.4 ± 9.2 |
| Men, n (%) | 404 (59.6) | 376 (54.4) |
| Race, n (%) | ||
| American‐Indian or Alaskan Native | 2 (0.3) | 2 (0.3) |
| Asian | 30 (4.4) | 25 (3.6) |
| Black or African‐American | 50 (7.4) | 42 (6.1) |
| Multiple | 9 (1.3) | 5 (0.7) |
| Native Hawaiian or Other Pacific Islander | 2 (0.3) | 2 (0.3) |
| White | 585 (86.3) | 615 (89.0) |
| Hispanic or Latino ethnicity, n (%) | 78 (11.5) | 74 (10.7) |
| Weight, kg | 95.8 ± 19.5 | 96.1 ± 19.8 |
| Body mass index, kg/m2 | 33.0 ± 5.6 | 33.3 ± 5.7 |
| Duration of diabetes, years | 14.2 ± 7.8 | 14.1 ± 7.0 |
| HbA1c ≤8.5%, n (%) | 396 (58.4) | 426 (61.6) |
| Basal insulin at baseline, n (%) | ||
| Glargine | 329 (49) | 345 (50) |
| NPH (Isophane) | 90 (13) | 87 (13) |
| Detemir | 97 (14) | 90 (13) |
| Insulin premix | 121 (18) | 136 (20) |
| Other | 2 (<1) | <1 (<1) |
| Baseline number of insulin injections, n (%) | ||
| 1 | 160 (23.6) | 171 (24.7) |
| 2 | 134 (19.8) | 136 (19.7) |
| ≥3 | 384 (56.6) | 384 (55.6) |
| Bolus insulin dosing plan, n (%) | ||
| Carbohydrate counting | 93 (14) | 104 (15) |
| Preprandial action plan with fixed diet | 172 (25) | 167 (24) |
| Pattern adjustment plan | 413 (61) | 420 (61) |
| Lipid‐lowering medications, n (%) | ||
| Statins | 421 (62.1) | 429 (62.1) |
| Non‐statin lipid lowering medications | 124 (18.3) | 122 (17.7) |
| Hypertension, n (%) | 577 (85.1) | 590 (85.4) |
BIL, basal insulin peglispro; HbA1c, glycated haemoglobin.
Data are mean ± standard deviation, unless otherwise noted.